KCFA
HUMA icon

Key Client Fiduciary Advisors’s Humacyte HUMA Stock Holding History

Key Client Fiduciary Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.15K Buy
+11,720
New +$10.9K ﹤0.01% 231

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Key Client Fiduciary Advisors's HUMA Position: Q2 2026 in Review

Key Client Fiduciary Advisors opened a new position in Humacyte (HUMA) in Q2 2026: 11,720 shares worth $9.15K. The stake represents ﹤0.01% of the portfolio and ranks #231 among its holdings.

163 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Key Client Fiduciary Advisors held 11,720 shares of Humacyte worth $9.15K as of Q2 2026.
  • Humacyte was a new Key Client Fiduciary Advisors position in Q2 2026.
  • Humacyte made up ﹤0.01% of Key Client Fiduciary Advisors's portfolio in Q2 2026, its #231 holding.
  • 163 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Key Client Fiduciary Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.